Urease inhibitors: current advances, therapeutic potentials, and clinical challenges.

Area of Science:

• Biochemistry and Medicinal Chemistry
• Enzyme Inhibition
• Drug Discovery

Background:

• Urease, a nickel-dependent enzyme, facilitates urea hydrolysis, producing ammonia and increasing local pH.
• This process is a key factor in *Helicobacter pylori*-associated peptic ulcer disease (PUD).
• Acetohydroxamic acid (AHA) is the sole FDA-approved urease inhibitor, but its clinical use is limited by toxicity.

Purpose of the Study:

• To review and synthesize current evidence on diverse urease inhibition strategies.
• To evaluate the potential of various compounds and approaches for therapeutic applications.
• To identify challenges and future directions for developing effective urease inhibitors.

Main Methods:

• Comprehensive literature review of urease inhibition strategies.
• Analysis of metal-based complexes, organic derivatives, natural products, peptide inhibitors, nanotechnology, and gene-based approaches.
• Evaluation of preclinical data for promising candidates like copper compounds and palmatine (PAL).

Main Results:

• Multiple strategies show potent urease inhibition in preclinical models, including copper complexes and palmatine.
• Challenges to clinical translation include safety concerns, compound instability, and limited human trials.
• Hybrid molecules, advanced delivery systems, and combination therapies are potential avenues for enhanced efficacy.

Conclusions:

• Urease inhibition presents a viable therapeutic strategy for urease-mediated diseases.
• Further rigorous clinical evaluation is essential to overcome current limitations.
• Development of safer, more stable, and clinically validated urease inhibitors is crucial.